Technical Analysis for DARE - Dare Bioscience, Inc.

Grade Last Price % Change Price Change
C 4.16 -1.65% -0.07
DARE closed down 1.65 percent on Friday, November 1, 2024, on 66 percent of normal volume. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.
Earnings due: Nov 7
*** please verify all earnings dates ***
1 Watcher
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Strong Down Up Up

Date Alert Name Type % Chg
Boomer Buy Setup Bullish Swing Setup 0.00%
Upper Bollinger Band Walk Strength 0.00%
Wide Bands Range Expansion 0.00%
Gapped Up Strength 0.00%
Overbought Stochastic Strength 0.00%
Upper Bollinger Band Touch Strength 0.00%
Jack-in-the-Box Bullish Bullish Swing Setup -1.65%
Doji - Bearish? Reversal -1.65%
Upper Bollinger Band Walk Strength -1.65%
Wide Bands Range Expansion -1.65%

   Recent Intraday Alerts

Alert Time
Down 2 % about 20 hours ago
Down 1% about 20 hours ago
Possible NR7 about 22 hours ago
60 Minute Opening Range Breakdown about 22 hours ago
Up 1% 1 day ago

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Dare Bioscience, Inc. Description

Dare Bioscience, Inc., formerly Cerulean Pharma Inc., is a healthcare company. The Company is focused on the development and commercialization of products in women’s reproductive health. Its lead product candidate is Ovaprene, a clinical stage, non-hormonal contraceptive ring. The Company is developing Ovaprene to provide protection over multiple weeks of use and require no intervention at the time of intercourse. Ovaprene has a custom intravaginal ring design, with a permeable mesh in the center of the ring that creates a partial barrier to sperm, and a mechanism to release locally acting spermiostatic agents through the ring. The combination of these two complementary approaches produces attractive contraceptive efficacy outcomes that are consistent with the effective barrier option, the diaphragm, and short-acting hormonal options, such as oral pill, patches and vaginal ring.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Drugs Birth Control Vagina Women's Health Diaphragm Hormonal Contraception Medroxyprogesterone Acetate

Is DARE a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 7.56
52 Week Low 3.05
Average Volume 34,595
200-Day Moving Average 4.30
50-Day Moving Average 3.47
20-Day Moving Average 3.65
10-Day Moving Average 3.86
Average True Range 0.19
RSI (14) 70.33
ADX 49.97
+DI 33.56
-DI 7.61
Chandelier Exit (Long, 3 ATRs) 3.70
Chandelier Exit (Short, 3 ATRs) 3.76
Upper Bollinger Bands 4.25
Lower Bollinger Band 3.05
Percent B (%b) 0.92
BandWidth 32.84
MACD Line 0.20
MACD Signal Line 0.13
MACD Histogram 0.07
Fundamentals Value
Market Cap 410.02 Million
Num Shares 98.6 Million
EPS -0.48
Price-to-Earnings (P/E) Ratio -8.67
Price-to-Sales 36.27
Price-to-Book 3.44
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 4.43
Resistance 3 (R3) 4.44 4.36 4.39
Resistance 2 (R2) 4.36 4.29 4.36 4.37
Resistance 1 (R1) 4.26 4.25 4.22 4.25 4.35
Pivot Point 4.18 4.18 4.16 4.18 4.18
Support 1 (S1) 4.08 4.11 4.04 4.07 3.97
Support 2 (S2) 4.00 4.07 4.00 3.95
Support 3 (S3) 3.90 4.00 3.94
Support 4 (S4) 3.89